statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Galectin Therapeutics in a report released on Monday...

FY2025 EPS Estimates for Galectin Therapeutics Inc. Lowered by Analyst (NASDAQ:GALT)

Retirement Guys Formula LLC grew its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 87.0% during the fourth quarter, according to the company in its most recent 13F...

Retirement Guys Formula LLC Boosts Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT)

Galectin Therapeutics (NASDAQ:GALT - Get Free Report)s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They...

Galectin Therapeutics (NASDAQ:GALT) Rating Reiterated by HC Wainwright

Galectin Therapeutics GAAP EPS of -$0.74...

Galectin Therapeutics GAAP EPS of -$0.74

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results...

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Comparing GALT's Performance Against Analyst Estimates and Exploring Future ProspectsRelated Stocks: GALT...

Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments

StockNews.com downgraded shares of Galectin Therapeutics (NASDAQ:GALT  Free Report) from a hold rating to a sell rating in a research report report published on Monday. Galectin Therapeutics...

Galectin Therapeutics (NASDAQ:GALT) Lowered to Sell at StockNews.com

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of...

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Galectin Therapeutics (NASDAQ:GALT  Get Free Report) and Xilio Therapeutics (NASDAQ:XLO  Get Free Report) are both small-cap medical companies, but which is the superior investment? We...

Contrasting Galectin Therapeutics (NASDAQ:GALT) and Xilio Therapeutics (NASDAQ:XLO)

AE Wealth Management LLC grew its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT  Free Report) by 72.7% in the 3rd quarter, according to the company in its most recent...

AE Wealth Management LLC Has $52,000 Stake in Galectin Therapeutics Inc. (NASDAQ:GALT)

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Volume	35,209.00
52-Wk High	$4.27
52-Wk Low	$1.28

GALT Galectin Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals